Abnormalities in glomerular function have been observed frequently in the early stages of both clinical and experimental diabetes mellitus. Because prostaglandins (PGs) are present in the glomerulus and have profound effects on glomerular hemodynamics, and because abnormalities of PG metabolism have been noted in other tissues from diabetics, we studied PG biosynthesis in glomeruli obtained from rats in the early stages of experimental diabetes mellitus. Streptozotocin, 60 mg/kg, was administered intravenously to male Sprague-Dawley rats. Control rats received an equal volume of the vehicle. Glomeruli were isolated 9-23 d later. Production of eicosanoids was determined by two methods: by direct radioimmunoassay after incubation of glomeruli under basal conditions and in the presence of arachidonic acid (C20:4), 30 pM, and by radiometric high-performance liquid chromatography (HPLC) after incubation of glomeruli with ['4C]C20:4. When assessed by radioimmunoassay, mean basal production of both prostaglandin E2 (PGE2) and prostaglandin F2. (PGF2.) was twofold greater in the diabetic animals whereas production of thromboxane B2 (TXB2) was not significantly greater than control. In response to C20:4, both PGE2 and PGF7, were also greater in the diabetic animals, but these differences were not statistically significant. The increased rate of basal PG production did not appear to be related directly to the severity of the diabetic state as reflected by the degree of hyperglycemia at the time of sacrifice. In fact, the rates of glomerular PG production in the individual diabetic animals correlated inversely with the plasma glucose concentration. The increased rate of PG synthesis did not appear to be due to a nonspecific effect of streptozotocin inasmuch as glomerular PG production was not increased significantly in streptozotocin-treated rats which were made euglycemic by insulin therapy. Furthermore, addition of streptozotocin, 1-10 mM, to the incubation media had no effect on PGE2 production by normal glomeruli. PGE2 production by normal glomeruli was also not influenced by varying the glucose concentration in the incubation media over a range of 1-40 mM. When metabolism of I'4C1C20:4 was evaluated by high-performance liquid chromatography conversion to labeled PGE2, PGFu,, TXB2, and hydroxyheptadecatrienoic acid by diabetic glomeruli was two-to threefold greater compared with that in control glomeruli, whereas no significant difference in conversion to 12-and 15-hydroxyeicosatetraenoic acid occurred. These findings indicate that glomerular cyclooxygenase but not lipoxygenase activity was increased in the diabetic animals. A concomitant increase in glomerular phospholipase activity may also have been present to account for the more pronounced differences in PG production noted in the absence of exogenous unlabeled C20:4. These abnormalities in PG biosynthesis by diabetic glomeruli may contribute to the altered glomerular hemodynamics in this pathophysiologic setting.
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Introduction
Abnormalities of glomerular function are prominent features of diabetes mellitus. In addition to the progressive loss of functioning nephrons that occurs in many patients with longstanding type I or insulinopenic diabetes (1) , an increase in glomerular filtration rate (GFR)1 and renal blood flow has been observed repeatedly in such patients in the earlier stages of this disorder (2) (3) (4) . Similar increases in both whole kidney (5) and single nephron GFR and glomerular plasma flow rate (6, 7) have also been demonstrated in the early stages of an experimental model of diabetes mellitus in the rat, and these hemodynamic alterations have been implicated in the pathogenesis of the glomerular damage that occurs in the later stages of the disease (8) .
Recently, decreased responsiveness to the renal vasoconstrictor effects of angiotensin II has also been observed in diabetic rats (9) , a finding that may be explained in part by the demonstration that the density of receptors for angiotensin II is decreased in diabetic glomeruli (10). These findings accord with the hypothesis that the abnormalities in glomerular function characteristic of early diabetes may be initiated by alterations in the effects of vasoregulatory hormones such as angiotensin II, which might be expected to affect glomerular hemodynamics (1 1), as well as by hyperglycemia-induced extracellular volume expansion, structural hypertrophy of the kidney, and altered glucoregulatory hormones (8) . That hyperglycemia per se may affect glomerular function is evidenced by the increased GER documented to occur with infusion of glucose in both normal subjects and insulin-dependent diabetics (12) and by the reduction in elevated levels of GFR and renal plasma flow that results when glucose levels are normalized by acute insulin therapy in type I diabetics, but not when glucose levels are prevented from falling by concomitant glucose infusions (13). In addition to hyperglycemia, the diabetic state is characterized by increased circulating levels of glucoregulatory hormones such as growth hormone and glucagon, both of which can increase GFR (14) (15) (16) . Thus, the alteration of glomerular function in patients with diabetes is probably multifactorial in nature.
Glomeruli isolated from rat and human renal cortex metabolize arachidonic acid (C20:4) into prostaglandins (PGs) through the cyclooxygenase pathway (17) (18) (19) Nonfasting plasma glucose samples were obtained one to two times per week by retro-orbital sinus puncture under lightly administered ether anesthesia and by aortic puncture at the time of death. Marked hyperglycemia occurred promptly in the rats that received streptozotocin and tended to increase further during the subsequent weeks of observation (Fig. 1) . Only those rats in which plasma glucose levels exceeded 350 mg/dl were included in the diabetic group.
Additional experiments were carried out to evaluate a possible effect of streptozotocin, rather than of the diabetic state per se, on glomerular PG production. Beginning on day 3, half of each group of diabetic rats were given neutral protamine Hagedorn insulin in doses (2-5 U, subcutaneously, each evening) that were adjusted, on the basis of frequent whole blood glucose measurements (Accu-Chek bG, BioDynamics, Boehringer-Mannheim Corp., Indianapolis, IN), to render them euglycemic. The remaining diabetic rats were untreated, and a third group of age-and weight-matched rats that had received the vehicle served as controls.
Glomerular preparations. Glomeruli were isolated 9-23 d after administration of streptozotocin. Under pentobarbital anesthesia (50 mg/kg of body wt, intraperitoneally), the kidneys were perfused with isotonic cold, heparinized saline until blanched (30-50 ml saline in 2-3 min) (31) . Glomerular preparations were obtained either from individual rats or from pools obtained from two to three diabetic rats and an equivalent number of control rats. Kidneys from the diabetic and control rats were perfused alternately and no more than six rats were used in a single experiment. No systematic effect of the order of preparation was observed.
Glomeruli were isolated as described previously (17) . In brief, for each preparation the renal cortices from one to three rats (two to six kidneys) were dissected and minced to a pastelike consistency. The homogenate was passed successively through a 106-,gm sieve that excluded the tubules and blood vessels and a 75-um sieve that retained the glomeruli and allowed cells and small debris to pass through. Glomeruli were suspended in ice-cold 20 mM Tris HCG buffer, pH 7.4, containing 135 mM NaCl, 10 mM KCI, 10 mM sodium acetate, and 5 mM glucose (buffer A) and centrifuged at 120 g for 2 min. The supernatant was discarded and the pellet was resuspended in the same buffer and recentrifuged. The resultant pellet, which consisted of isolated decapsulated glomeruli with <5% tubular contamination, was utilized immediately for studies of C20:4 metabolism. For the studies using direct radioimmunoassay, glomeruli were resuspended in 1-2 ml of buffer A with I mM CaCl2 and incubated in 250-500-Ad aliquots (0.2-0.7 mg of glomerular protein) in the absence (basal conditions) or presence (stimulated conditions) ofC20:4, 10 sg/ml (30 AM). Incubations were carried out in room air for 30 min at 370C in a water-bath shaker and were stopped by immediately immersing the tubes in ice followed by centrifugation at 22,000 g at 40C for 2 min. Supernatants from each tube were collected and frozen until radioimmunoassay was performed. PGE2 and PGF2, were measured directly in the supernatant without further purification by the method of Dray et al. (32) and TXB2 by the method of Sors et al. (33) .
For the studies of conversion of ["4C]C20:4 to PGs and other eicosanoids, pools of glomeruli from diabetic and control rats were resuspended in buffer A and incubated in l-ml aliquots (2.0-5.0 mg of glomerular protein) in the presence of 5 mM CaCl2 and 1.6 pCi ["4CJC2O:4. Incubations were carried out in room air for 30 min at 370C in a water-bath shaker and were stopped by precipitation with 2 ml of cold methanol and centrifugation at 22,000 g for 2 min. The supernatant was removed and the pellet was rewashed with 1 ml of methanol and recentrifuged. The supernatants were pooled, acidified to pH 3.0-3.5 with 1 N HCG, and after addition of 4 ml of distilled water, were extracted twice with 6 ml of diethyl ether. The ether layers were then pooled and evaporated to dryness in a nitrogen stream.
Column chromatography. Silicic acid column chromatography was performed in glass columns packed with 0. The purified residue from fraction II was dissolved in HPLC solvent D (water/acetonitrile/benzene/acetic acid, 790:230:2:1, vol/vol/ vol) and 100 Al was injected directly into the chromatograph. The reverse-phase column (Spherisorb S5C6, 25 cm X 4.9 mm i.d., Phase Separations, Mauppauge, NY) was eluted isocratically at a flow rate of i.8 mlI/min and the products were identified by co-migration with authentic 3H-PG standards. Fractions were collected every minute and "C-radioactivity of each fraction was measured. After 50 min the column was washed with pure acetonitrile.
Data analysis. In studies in which the rate of PG production was determined by radioimmunoassay, the results were expressed as picograms/milligram of protein per 30-min incubation. Glomerular protein was measured by the method of Lowry et al. (34) using bovine serum albumin as the standard. In preliminary experiments, it was determined that the ratio of the number of glomeruli to the amount of glomerular protein was not significantly different in diabetic and control animals: diabetic rats, 12.1±2.8 glomeruli per microgram of protein, n = 6; diabetic rats treated with insulin, 11.6±2.0, n = 4; control rats 15.9±3.6, n = 6.
In studies in which the rates of transformation of ["C]C20:4 into labeled PGs and other eicosanoids were studied by radiometric HPLC, the results were expressed as counts per minute per milligram of protein per 30-min incubation. The area under the curve for each product was calculated as the sum of the counts per minute for each tube comprising that peak minus the baseline radioactivity level.
Statistical analysis was performed using Student's t test, the MannWhitney test, and linear regression analysis as appropriate (35) .
Results
Determination ofPG production by direct radioimmunoassay. Under basal conditions, glomerular PG production was increased in diabetic rats. This difference was apparent both in studies employing glomerular preparations from individual rats, and in those using pools of glomeruli from diabetic and control animals. In the studies performed in individual rats, the mean production rates of both PGE2 and PGF2, the major PGs produced by rat glomeruli, were approximately twofold greater in the rats with diabetes whereas that of the TXB2 was not significantly greater than control (Table I) . Production of PGE2 was also measured on the supernatant obtained from incubation of pools of glomeruli from diabetic and control rats. In these studies, mean basal PGE2 production was also approximately twofold greater in glomeruli from diabetic animals (1619±301 vs. 707±93 pg/mg of protein per 30-min incubation, n = 7, P < 0.02).
The increased rate of basal PG production did not appear to be related directly to the severity of the diabetic state as reflected by the degree of hyperglycemia at the time of death. In fact, the rates ofglomerular PG production in the individual diabetic animals correlated inversely with the plasma glucose concentration (r = -0.67, P < 0.05 for PGE2; r = -0.88, P < 0.001 for PGF2.) (Fig. 2) . Furthermore, in separate studies we determined that PGE2 production by normal glomeruli was not influenced by the glucose concentration in the incubation media over a range of 1-40 mm (18-720 mg/dl) ( Table II) .
The increased rate of PG production did not appear to be due to a nonspecific effect of streptozotocin inasmuch as glomerular PG production was not increased significantly in streptozotocin-treated rats made euglycemic with insulin therapy. The mean plasma glucose concentration in those animals (179±77 mg/dl, n = 10) did not differ significantly from that of the controls (160±4, n = 10) in contrast to the marked hyperglycemia (590±18, n = 12) in the untreated diabetic rats. Production rates of PGE2 (845±206 vs. 689±88 pg/mg of examined using a reverse-phase system, no qualitative differences in the profiles obtained from diabetic and control glomeruli were noted. The profiles obtained in control rats in the present study were similar to those reported previously from our laboratory using glomeruli obtained from normal rats (Fig. 3, left) . After an initial peak that represents an autooxidation product of ['4C]C20:4, between five and eight peaks could be distinguished during a subsequent 50-60-min elution. Five peaks with retention times of 11, 30, 36, 45, and 50 min were identified by co-migration with 3H-standards as 6-keto-PGFI,., TXB2, PGF2., PGE2, and PGD2, respectively. This pattern of elution was nearly identical in glomeruli obtained from diabetic rats (Fig. 3, right) . Whereas no differences in the general patterns of PG production were noted, incorporation of ['4C]C20:4 into the major PGs was increased in the diabetic glomeruli (Table IV) . When conversion of ['4C]C20:4 into lipoxygenase products and other eicosanoids was studied using a straight-phase system, there were again no differences in the patterns of 14C-products between control and diabetic preparations. As previously reported from our laboratory (20), at the high substrate concentration used in these experiments, glomeruli from normal rats form predominantly 12 PGF2., PGE2, and PGD2, respectively. Two large peaks (XI and X2) eluting between 6-keto-PGFI and TXB2, were also present as noted previously for rat glomeruli (38) . These remain unidentified but are thought likely to be products of cyclooxygenase activity inasmuch as they are suppressed by addition of indomethacin to the incubation mixture. On the right panel, the figure in parentheses next to peak
Xi indicates the magnitude of this product.
11 and 13 min, directly after a large peak of unreacted C20:4 (Fig. 4, left) . A minor peak (eluting at 17 min) corresponded to the retention time of 11-HETE. An additional major peak (eluting at 26 min) was noted consistently, using the chromatographic system employed in the present studies. This peak co-migrated with both 8-HETE and HHT standards in this system. When this peak was collected and reinjected into a reverse phase system (MicroPak MCH-10), it was evident that the product formed by both the diabetic and control glomeruli was entirely HHT. Similar to the PGs, conversion to HHT was increased in diabetic glomeruli (Table IV) . In contrast, no significant difference in the rate of formation of the lipoxygenase products was observed.
Discussion
The results of our study indicate that the synthesis of PGs is altered in glomeruli isolated from rats with streptozotocininduced diabetes mellitus and that the abnormalities are a consequence of the diabetic state rather than of the agent used to produce it. Production rates of both PGE2 and PGFu, the major PGs produced by rat glomeruli, were increased two-to threefold whether estimated by direct radioimmunoassay (Table  I) or by incorporation of ['4CJC20:4 into labeled eicosanoids (Table III) . Production of TXB2, the stable metabolite of thromboxane A2 (TXA2), appeared to also be increased but this difference was only statistically significant in the studies employing radiometric HPLC. The pattern of radiolabeled products formed after incubation with ['4CJC20:4 suggests a specific augmentation of glomerular cyclooxygenase but not lipoxygenase activity. Our data do not exclude a concomitant increase in glomerular phospholipase activity which, if present, might account for the more pronounced difference in PG production noted in the absence of exogenous unlabeled C20:4.
Our finding that glomerular PG synthesis is altered in diabetic rats is in accordance with the numerous observations of abnormalities in PG metabolism that occur in both clinical and experimental diabetes. Increased release of PGE2 and prostaglandin I2 (PGI2) by adipocytes in rats with diabetic ketoacidosis has been inferred by the observation that elevated plasma levels of derivatives of these compounds are suppressed by both insulin and 5-methylpyrazole-3-arboxylic acid, two potent and structurally unrelated antilipolytic compounds (39) . Abnormalities of eicosanoid metabolism by platelets are also well described in diabetes. Platelets obtained from diabetic patients release more PGE-like material in response to aggregatory stimuli than do those obtained from normal subjects (23) . Increased synthesis of TXA2, as gauged by levels of its stable metabolite TXB2, was also found in platelets obtained from humans with diabetes (24) and from rats with both streptozotocin-induced (40) and spontaneous (BB Wistar) diabetes (41) . The finding of increased platelet aggregation and release of malonyldialdehyde in newborn infants and their diabetic mothers compared with control mother-neonate pairs provides further evidence of enhanced thromboxane synthesis activity (42) . In contrast to increased synthesis of these proaggregatory eicosanoids by platelets, release of the potent antiaggregatory eicosanoid prostacyclin was decreased in arteries (25) and veins (26) of patients with diabetes mellitus, in umbilical arteries of neonates of mothers with either gestational or juvenile-onset diabetes (43, 44) , and in aortic tissues obtained from rats (45, 46) and swine (47) with streptozotocin-induced diabetes. In the pancreas a possible role for abnormalities of PG metabolism in the pathophysiology of impaired insulin secretion in diabetics has been inferred from the observation that PGE infusion inhibits glucose-induced acute insulin responses in normal human subjects and infusion of sodium salicylate partially restores the acute insulin response to glucose infusion in type II diabetics (48) . Similarly, changes in PG metabolism in lung (49) (50) (51) , heart (52), and seminal vesicles eluting at 26 min, co-migrated with both 8-HETE and HHT standards in this system. When this peak was collected and injected into a reverse-phase system, it was determined to be entirely HHT.
(53) may also contribute to altered function of these organs in diabetics.
Despite the substantial evidence for abnormalities in PG production in other tissues from diabetics, relatively little attention has been paid to possible alterations in renal PG metabolism in this disorder. In humans such observations have been limited to measurement of the urinary excretion of PGE2, which has been variously reported to be reduced (54, 55) or normal (56, 57) in patients with diabetic nephropathy. However, interpretation of even these few reports is made difficult by the uncertainty as to the site of origin of the urinary prostanoids, by the technical issues raised by inclusion of male subjects (58), and by the fact that these studies were performed in the chronic stages of the disease when glomerular function was compromised significantly. In the rat microsomal preparations from whole kidney homogenates obtained in the first two weeks of both alloxan-and streptozotocin-induced diabetes mellitus released less PGE-like material when incubated with C20:4 than those from control animals (59). Production of PGI2 was also decreased in homogenates of renal cortex obtained from rats studied 1-3 mo after administration of streptozotocin (60) . It should be noted, however, that results of studies performed on either crude homogenates or microsomal preparations of whole cortex may reflect abnormalities in PG metabolism in structures other than the glomerulus. Thus, Rogers and Larkins (61) reported that release of 6-keto-PGF1. by glomeruli isolated from diabetic rats was not decreased compared with glomeruli from control rats. In fact, as noted by these investigators, mean production of both 6-keto-PGF1a and PGE2 under basal conditions and after stimulation by arachidonate was actually increased in diabetic rats, but the differences did not reach the level of statistical significance. Similar increases in glomerular synthesis of PGE2 and 6-ketoPGFia have now been confirmed by Kreisberg and Patel (62) and, in preliminary form, by Brown et al. (63) , and Chaudhari and Kirschenbaum (64). Taken together with the results of our study, it appears that, at least in the early stages of the disorder, glomerular PG synthesis is increased in glomeruli from diabetic rats.
The results of our studies do not identify the mechanism responsible for the increase in PG production by glomeruli. Inasmuch as PGs may function as modulators of the action of a variety of vasoactive substances, the increased PG synthesis we observed could represent a response to the systemic hemodynamic abnormalities that occur in severe diabetes. Although plasma volume per se is generally normal or increased in this setting (6), salt depletion, attending osmotic diuresis in severe diabetes, could conceivably be present independently of an alteration in intravascular volume. However, when salt depletion was induced in the rat by dietary restriction of NaCl (31), the pattern of PG synthesis by isolated glomeruli, namely an increase in PGF2a and a decrease in PGE2, was clearly different than that observed in our study. Furthermore, the highest PG production rates that we observed occurred in the rats with the least severe degrees of hyperglycemia (Fig. 2) , suggesting that the abnormalities were not related quantitatively to the disturbance of osmolality.
Alternatively, the abnormalities in C20:4 metabolism could result from the profound metabolic changes that occur in diabetes. A direct stimulatory effect of hyperglycemia seems unlikely in view of the negative correlation between blood glucose levels and the rate of PG synthesis (Fig. 2) and the absence of a stimulatory effect when the concentration of glucose was increased in the incubation media in vitro (Table  II) (62) . Furthermore, simply increasing the external concentration of glucose may bear little resemblance to the diabetic state in which intracellular glucose and ATP concentrations may be decreased as a consequence of insulin deficiency. That such hypoglycemic conditions might stimulate PG production is suggested by the finding that release of both PGE2 and PGF2, by renal papillae is stimulated by reduction of the glucose concentration of the media (65) and by the addition of inhibitors of glycolysis (66) . In other tissues such as vascular endothelium, the interaction between glucose concentration and PG release is even more complex, with stimulation occurring at concentrations between 10 and 30 mM with a subsequent decrease at higher concentrations (67). Production of PGs may be increased by activation of lipolysis as evidenced by the reduction of elevated plasma PG levels that occurred when antilipolytic agents were administered to rats with diabetic ketoacidosis (39) . PG production by diabetic tissues might be affected further by deficiency of C20:4 stores (68), a finding that might have contributed to the lower rates of PG release in our most severely diabetic animals. That any one or more of the many metabolic abnormalities that comprise the diabetic milieu in vivo could conceivably influence PG production, is suggested by the recent observation that prostacyclin production by human endothelial cells in culture was reduced when cultured in diabetic serum (69) .
Whether or not the biochemical abnormalities in glomerular PG metabolism observed in the diabetic animals in the present study contribute to the abnormalities in glomerular function reported by others (5-10) remains to be demonstrated. There is a considerable body of evidence that indicates that the filtration process is modulated by a variety of classic hormonal substances and by locally acting autacoids (1 1). Certain vasoactive hormones, such as angiotensin II, appear to be generated locally in the kidney as well as in the systemic circulation and may represent a common effector by which many hormones influence the GFR (11, 70). PGs, which are also produced locally in the kidney, can influence GFR by modification of the vasoconstrictor effects of angiotensin II (21) and by stimulation of renin secretion and local generation of angiotensin II, which reduces the glomerular capillary ultrafiltration coefficient (Kf) (70) . The reduction in Kf appears to be mediated by contraction of the glomerular mesangial cell, a cell that contains receptors for and contracts in response to angiotensin II (71, 72) . PGs, which are secreted by these same mesangial cells (73) (74) (75) , decrease the contractile responses of whole glomeruli to angiotensin II, and inhibitors of PG synthesis increase the response (76). TXA2, which is also produced locally in the kidney, is a potent vasoconstrictor and can also stimulate glomerular contraction directly (77) . Thus, although the preliminary observation that indomethacin reduces single nephron GFR when administered to diabetic rats (78) suggests a net vasodilatory effect of glomerular eicosanoids in this setting, further studies which evaluate the effect of inhibitors of specific enzymes in PG biosynthesis on glomerular hemodynamics will be required to better define the functional role of these compounds in diabetes.
